uniQure seeks US approval for Huntington's gene therapy after FDA reversal

uniQure is pursuing US FDA approval for its gene therapy targeting Huntington's disease following a reversal in the FDA's previous stance, signaling regulatory progress in gene therapies for rare neurological conditions.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.